The Australian National Antimicrobial Resistance Strategy calls for a collaborative effort to change practices that have contributed to the development of drug-resistance and for implementation of new initiatives to reduce antibiotic use.
Methods
A facilitated workshop was undertaken at the 2019 National Australian Antimicrobial Resistance Forum to explore the complexity of antimicrobial stewardship (AMS) implementation in Australia and prioritise future action. Participants engaged in rotating rounds of discussion using a world café format addressing six topics relating to AMS implementation. Once all tables had discussed all themes the discussion concluded and notes were summarised. The documents were independently openly coded by two researchers to identify elements relating to the implementation of antimicrobial stewardship.
Results
There were 39 participants in the facilitated discussions, including pharmacists, infectious disease physicians, infection prevention nurses, and others. Participants discussed strategies they had found successful, including having a regular presence in clinical areas, adapting messaging and implementation strategies for different disciplines, maintaining positivity, and being patient-focused. Many of the recommendations for the next step involved being patient focussed and outcomesdriven. This involves linking data to practice, using patient stories, using data to celebrate wins and creating incentives.
Discussion
Recommendations from the workshop should be included in priority setting for the implementation of AMS initiatives across Australia.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The Australian National Antimicrobial Resistance Strategy calls for a collaborative effort to change practices that have contributed to the development of drug-resistance and for implementation of new initiatives to reduce antibiotic use [1]. In Australia, achievements have included an expanded role of hospital pharmacists in supporting appropriate antibiotic prescribing—now mandated in national accreditation standards [2, 3], improvements in surveillance, including the introduction of the Antimicrobial Use and Resistance in Australia (AURA) Surveillance System [4, 5]; the use of electronic referral applications for audit and feedback rounds [6], and the introduction of processes for incorporating antimicrobial stewardship into discharge [7]. Nevertheless, progress more broadly has been slow and novel solutions are now required for improving clinical practice and community awareness in a sustainable fashion.
A facilitated workshop was undertaken at the 2019 National Australian Antimicrobial Resistance Forum to prioritise future directions for antimicrobial stewardship implementation in Australia. The forum brought together health professionals, veterinarians, policy makers, and others to promote effective action against antimicrobial resistance. Participants (n = 39)—including health professionals, veterinarians, policy makers, and others—engaged in rotating rounds of discussion using a world café format addressing six topics relating to AMS implementation (see Fig. 1) [8]. Once all tables had discussed all themes the discussion concluded, and notes were summarised. The documents were independently openly coded by two researchers to identify elements relating to the implementation of antimicrobial stewardship. An iterative approach was used to identify and reach consensus on emergent themes from the workshop. A summary of results was sent out to all workshop participants for feedback (see Additional file 1).
×
Anzeige
Topic 1: building rapport within hospital setting
Successful strategies observed by participants for building rapport within a hospital setting included having a regular presence in clinical areas, adapting messaging and implementation strategies for different disciplines and different levels of seniority, maintaining positivity, and being patient focused. Maintaining a priority status for AMS compared with other needs in a hospital setting is difficult. It can result in what one participant called “AMS fatigue”, where individuals becoming weary of hearing about the problem and so interest in AMS cannot be maintained. Recommendations for the next step involved being patient focussed and outcomes driven, linking data to practice, using patient stories, and using data to celebrate wins and creating incentives.
Topic 2: implementing in a resource limited hospital setting
Reported challenges in implementing AMS within a resource limited hospital setting, such as rural and remote hospitals, include lack of access to relevant expertise, burnout of healthcare workers, a high rate of staff turnover, and the most appropriate antibiotic as recommended by Therapeutic Guidelines not always being available [9] due to lack of supply. Participants suggested a centralised service to be formalised and resourced appropriately that would work to build relationships with the facilities and understand the local context. One of the roles of such a centralised service would be to provide education—whether remotely or in-person—to build local expertise.
Topic 3: implementing beyond the hospital setting
The groups discussed implementation of AMS beyond the hospital setting, including general practice, community pharmacy, and aged care. Participants identified that despite the differences in each of these settings they have shared challenges of fragmentation and misaligned incentives, and lack of access to services that may be available in a hospital setting. There are time pressures compounded by patient expectations of receiving antibiotics—it can seem faster and easier to “just prescribe”. Within community pharmacies, barriers to AMS include lack of financial motivation to minimise antibiotic use and changing business models leading to some pharmacies providing less patient support. Specific concerns in the aged care sector included high turnover of staff, widespread polypharmacy, and continuity of care, and the need for greater access to specialist AMS support. Participants discussed training, peer support and surveillance with feedback as strategies for implementing AMS in the community setting. The participants argued for the potential value of general practitioners and pharmacists having access to the same data.
Topic 4: engaging and empowering the public
Participants identified that there are challenges with health literacy regarding prevention of infections, appropriate treatments, and duration of symptoms. They argued that AMS needs to be reframed to engage and empower the public. They recommended using positive language with individualised messages to patient groups establishing expectations for patients and providing patients with strategies to manage colds and flus. The messaging to patients should be consistent across professional groups to minimise patient confusion and be available across multiple media.
Anzeige
Topic 5: leadership
Participants discussed how to develop and encourage AMS leadership at all levels and the role of AMS leadership organisations both nationally and state-wide. One of the challenges identified was the lack of role clarity between the different AMS leadership organisations, making it difficult to know who is responsible for what task and how to provide oversight for these organisations.
Topic 6: linking data with implementation strategies
The absence of funding, time, and expertise were identified as challenges with linking implementation strategies to data. It can be difficult to determine if differences in antibiotic prescribing are due to variation in clinical case mix rather than differences in the prescribing behaviour of clinicians. Good quality and relevant data is not sufficient; the data also needs to be disseminated—whether this be to executives, health professionals, or the public. Participants recommended that data be presented in a way that tells a story, considers cost-effectiveness, and highlights benefits to the patient, such as linking to patient outcomes.
Acknowledgements
Hosting of world café by the 2019 National Australian Antimicrobial Resistance Forum and the Queensland Statewide Antimicrobial Stewardship Program. Additional feedback on topics and facilitation of world café discussion by Fiona Gotterson, Noleen Bennett Christopher Accornero, William Franks, Daniel Stefanski, Sahra Ashley, Hunter Scammell, Leah Sharman, and Caitlin Lock.
Declaration
Competing interests
The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.
Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.
Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.
„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.
Update Innere Medizin
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.